Zobrazeno 1 - 10 of 52 pro vyhledávání: '"S. P. Glasser"'
1
On arterial physiology, pathophysiology of vascular compliance, and cardiovascular disease
Autor: S P, Glasser
Publikováno v: Heart disease (Hagerstown, Md.). 2(5)
Traditionally, the main emphasis in hypertension treatment has been on lowering diastolic blood pressure. Recently, this emphasis has been shifting toward systolic blood pressure and pulse pressure, the latter of which might be a better indicator of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d1db061c76059debbfd478b061cdcfa9
https://pubmed.ncbi.nlm.nih.gov/11728285
Zobrazit plný text záznamu
2
Circadian variations and chronotherapeutic implications for cardiovascular management: a focus on COER verapamil
Autor: S P, Glasser
Publikováno v: Heart disease (Hagerstown, Md.). 1(4)
The circadian variation in biologic functions (chronobiology) may play a large role in the pathogenesis and exacerbation of many different diseases. Traditional treatment regimens for medical conditions associated with circadian variation often do no
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a455b4450a9cc05c0507e7aa53b23ca6
https://pubmed.ncbi.nlm.nih.gov/11720629
Zobrazit plný text záznamu
4
Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group
Autor: S P, Glasser
Publikováno v: The American journal of cardiology. 80(12)
The effect of extended-release isosorbide mononitrate (ER-ISMN) on exercise tolerance 1 hour after dosing was compared with that of placebo in a multicenter, randomized, double-blind study of 151 patients with stable effort-induced angina. During a 9
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a055d3dfcba5c95f65573cddb0786edb
https://pubmed.ncbi.nlm.nih.gov/9416933
Zobrazit plný text záznamu
5
Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators
Autor: S P, Glasser, D D, Michie, U, Thadani, W M, Baiker
Publikováno v: The American journal of cardiology. 79(10)
Zatebridine selectively reduces resting and exercise heart rate without any other myocardial effects. In this study, despite significant reductions in resting and exercise heart rate, there were no clinically significant effects on myocardial ischemi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::be4be65827e359419e000a8b5fa17ad6
https://pubmed.ncbi.nlm.nih.gov/9165168
Zobrazit plný text záznamu
7
Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group
Autor: S P, Glasser, S N, Singh, D P, Humen
Publikováno v: Journal of clinical pharmacology. 37(1)
Fantofarone is a calcium channel antagonist of a class (sulfone indolizine) that is structurally different from the existing classes. The primary cardiac action of fantofarone is on the sinus node, although it is also a potent peripheral and coronary
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ce2a212eefce28d8face63977b6252fb
https://pubmed.ncbi.nlm.nih.gov/9048273
Zobrazit plný text záznamu
8
The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group
Autor: S P, Glasser, A, Jain, K S, Allenby, T, Shannon, K, Pride, P P, Pettis, L A, Schwartz, E P, MacCarthy
Publikováno v: Clinical therapeutics. 17(1)
The efficacy and safety of two sustained-release formulations of nifedipine, the coat-core system (NIF CC) and the gastrointestinal therapeutic system (NIF GITS), were examined in 228 patients with mild-to-moderate essential hypertension in this 16-w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4f7d1bce97e9ccef49465c7cdbd6a193
https://pubmed.ncbi.nlm.nih.gov/7758054
Zobrazit plný text záznamu
9
Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. The Angina and Silent Ischemia Study Group (ASIS)
Autor: S, Borzak, T, Fenton, S P, Glasser, T L, Shook, G, MacCallum, P M, Young, P H, Stone
Publikováno v: Journal of the American College of Cardiology. 21(7)
We sought to define the extent to which the therapeutic efficacy of three single-drug regimens on ambulatory ischemia paralleled efficacy on other clinical manifestations of ischemia, specifically exercise test performance and anginal symptoms.Some s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c64c45b34c1b0727d1cdb626b814f0dc
https://pubmed.ncbi.nlm.nih.gov/8496526
Zobrazit plný text záznamu
10
Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials
Autor: S P, Glasser, P I, Clark, R J, Lipicky, J M, Hubbard, S, Yusuf
Publikováno v: JAMA. 265(12)
Because the safety of withholding standard therapy and enrolling patients with stable angina in placebo-controlled trials is not known, we identified all events leading to dropout from trials of 12 antianginal drugs submitted in support of new drug a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8404b782bb63f168bf376dacf7712178
https://pubmed.ncbi.nlm.nih.gov/1671885
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje